Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.
Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30(+) lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34(+) stem cells and hematopoietic engraftment after autologous stem cell transplantation (ASCT). We examined 42 patients treated with BV before mobilization. Median times from diagnosis to transplantation, from initial BV treatment to transplantation, and from last BV treatment to stem cell collection were 21 months (range, 10 to 210), 5 months (range, 1.5 to 16.8), and 30 days (range, 2 to 280), respectively. Mobilization was successful on the first attempt in 38 patients (90.4%). The median number of infused CD34(+) cells was 5.46 × 10(6)/kg (range, 1.65 to 54.78 × 10(6)/kg). The median times to neutrophil and platelet engraftment were 10 (range, 9 to 13), and 10.5 days (range, 7 to 35), respectively. BV before high-dose chemotherapy-ASCT did not adversely affect peripheral blood stem cell mobilization and subsequent engraftment in a cohort of heavily pretreated patients with CD30(+) lymphomas.
University Hospitals Seidman Cancer Center, Cleveland, Ohio.
Manuel
M
Afable
University Hospitals Seidman Cancer Center, Cleveland, Ohio.|Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Paolo F
PF
Caimi
Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chitra
C
Hosing
University Hospitals Seidman Cancer Center, Cleveland, Ohio.|Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Marcos
M
de Lima
Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Issa
I
Khouri
University Hospitals Seidman Cancer Center, Cleveland, Ohio.|Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Basem M
BM
William
Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Yago
Y
Nieto
University Hospitals Seidman Cancer Center, Cleveland, Ohio.|Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Brenda W
BW
Cooper
Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Paolo
P
Anderlini
University Hospitals Seidman Cancer Center, Cleveland, Ohio.|Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Stanton L
SL
Gerson
University Hospitals Seidman Cancer Center, Cleveland, Ohio.|Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Hillard M
HM
Lazarus
Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Richard
R
Champlin
Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Uday
U
Popat
D000293:Adolescent; D000328:Adult; D000368:Aged; D000079963:Brentuximab Vedotin; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013234:Stem Cells / Q000378:metabolism*; D019172:Transplantation Conditioning / Q000379:methods*; D055815:Young Adult
D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin
Autologous transplantation; Brentuximab; Mobilization